BRETT CARTER to Treatment Outcome
This is a "connection" page, showing publications BRETT CARTER has written about Treatment Outcome.
Connection Strength
0.099
-
Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer. Radiol Clin North Am. 2018 May; 56(3):485-495.
Score: 0.036
-
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022 07 11; 40(7):754-767.e6.
Score: 0.012
-
Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 05; 23(3):236-243.
Score: 0.012
-
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67.
Score: 0.011
-
Outcomes to first-line pembrolizumab in patients with PD-L1-high (=50%) non-small cell lung cancer and a poor performance status. J Immunother Cancer. 2020 08; 8(2).
Score: 0.011
-
Lung Cancer: Posttreatment Imaging: Radiation Therapy and Imaging Findings. J Thorac Imaging. 2017 Sep; 32(5):288-299.
Score: 0.009
-
The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2017 01; 44(1):71-80.
Score: 0.008